Sanofi US News

Record-breaking holiday gift drive responds to increased homelessness rates

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies

New 24 and 32-Packs Designed to Manage Dosage Regimens for both Latent and Active Tuberculosis

- A study conducted with 1,500 Americans in July 2015 examined perceived risks of counterfeit medicines[1] -

- 74 percent of patients reached their LDL cholesterol goals on 75 mg dose; Of the remaining patients whose dose was adjusted to 150 mg, most achieved their goal -

- Data Show Significant Improvement in Signs and Symptoms and Physical Function in Rheumatoid Arthritis Patients who were Inadequate Responders to or Intolerant of TNF-Alpha Inhibitors (TNF-IR) -

- First New Drug Application for a GLP-1 receptor agonist to include CV outcomes data -

- Crucial vaccination with Raboral V-RG® continues to help protect wildlife and people against this fatal disease

New National Council on Aging Survey Shows Many Seniors Underestimate the Seriousness of the Flu, Largely Unaware of Vaccine Options1

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -

- Will work together on new digital technology and tools for diabetes -

- Praluent available early next week to U.S. patients -

- Leading influenza vaccine manufacturer to distribute more than 65 million doses to help protect people six months and older against the flu -

Sanofi and Regeneron Engage Academy Award® Winning Documentarian to Capture Behind-the-Scenes Look at Life with an Invisible Condition

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -

- Includes study in patients who were inadequate responders to, or intolerant of, TNF-alpha inhibitors -

- Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway -

Despite CDC recommendations, fewer than 30% of teens received the second vaccination to help protect against meningococcal meningitis; new survey reveals potential reasons why

U.S. Patent and Trademark Office Honors Sanofi for its Anti-Malarial Treatment

Approval allows children to receive a combination of two recommended vaccinations

- Results support resubmission of U.S. New Drug Application in Q3 2015 -

Allergy sufferers are encouraged to share the #HappySmells they experience this season

- Robust and consistent LDL-C lowering demonstrated with Praluent™ in largest, double-blind, placebo-controlled trial of a PCSK9 inhibitor to date -

View the Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S.

America's Leading National Consumer Research Survey Ranks Gold Bond Products #1 in "U.S. Body Comfort and Relief" and "U.S. Skincare" Categories